| 158.76 Data as of Jun 19 |  -3.11 / -1.92%Today’s Change | 135.77 Today|||52-Week Range 194.44 | -2.73% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $69.8B |
Company Description
Novo Nordisk AS is engaged in the development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes Care and Biopharmaceuticals segments. The Diabetes Care segment deals with the research, development, manufacture, and marketing of products within the areas of insulin, glucagon-like-peptide 1 and related delivery systems, oral anti-diabetic products, and obesity. The Biopharmaceuticals segment handles the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation and other therapy areas. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Employees
Shareholders
| Other institutional | 5.64% |
| Mutual fund holders | 3.25% |
| Individual stakeholders | -- |
Top Executives
| Lars Rebien Sørensen | President & Chief Executive Officer |
| Kåre Schultz | Chief Operating Officer & Executive Vice President |
| Jesper Brandgaard, MBA | Chief Financial Officer & Executive Vice President |
| Lars Fruergaard Jørgensen, MBA | Chief Information Officer & Executive VP |
| Kristina Lee | Vice President-Strategic Research & Development |
.
